News

Investment research, investor relations and consulting firm Edison Group initiates research on Exopharm.

“With its foundation LEAP technology, Exopharm has arguably the world’s best tools for manufacturing exosomes,” Pitt Street analysts Stuart Roberts and Cheng Ge wrote. We are proud to be at the forefront of the emerging exosome medicines field and for the many opportunities ahead. Click here for the full Stockhead article.    

Pitt Street Research has published a 29-page report on Exopharm. Base case valuation of $2.80 per share ($0.66 today), driven by the company’s LEAP technology.   Access the full Pitt Street Report here. To go to the Pitt Street Research page, click here.      

“Dr Laitinen and her team are the perfect first partners for manufacturing Plexaris and other blood EV products for Europe. We are equally excited to be preparing to transfer the LEAP technology to FRCBS so they can produce blood cell derived EV medicines,” said Dr Chris Baldwin, Chief Commercial Officer. “For Exopharm, this is the first […]

“I was more driven last year than ever before to really find that anti-viral to get it into the clinic”, said Dr. Ranja Salvamoser, Head of Experimental Biology. In light of International Women’s Day today, and every other day, we celebrate the work and achievements of the incredible women in our company. Ranja is leading her […]

“People have begun to understand that our destiny is not only in our hands, it is in the hands of the entire exosome research community, and everybody who is trying to develop exosome medicines, because there’s no technology that has been demonstrated that can produce thousands, much less tens of thousands or hundreds of thousands […]

“The biggest problem is to purify the EVs from their source and to eliminate the contaminants, and not damage the EVs,” says Managing Director and founder Dr Ian Dixon. One of the great things about our LEAP technology and process is that it is scalable. You can read the full Stockhead article here.

Chief Commercial Officer, Dr Chris Baldwin, will present to the Exosome Based Therapeutic Development Digital Summit on 11 November (9:00 AM US Eastern Time, 1.00 AM AEDT), the first day of the two-day event. You can find the slide deck here.  

“With a successful outcome from PLEXOVAL II, Exopharm will be well-positioned to initiate Phase 2 studies with off-the-shelf Plexaris and Phase 1 studies with our mesenchymal stem cell EV product Cevaris,” said Angus Tester, Head of Product Evaluation. You can read the full Stockhead article here.   

How mRNA vaccines could defeat the novel coronavirus   Head of Innovation Andy Coley spoke with Stockhead about the potential of mRNA for fighting COVID-19, including Moderna’s vaccine candidate and Fortrexo, our engineered EV approach. You can find the full article here.  

Exopharm has announced a placement of shares to raise $10 million. Canary Capital, the manager of the placement, and its directors have elected to take the majority of their fees in shares. “In Exopharm, Canary has identified an Australian company with proprietary technology that can compete on the world stage”, says Paul Hart, Executive Director […]

“As a serial biotechnology entrepreneur, Dr Dixon doesn’t just develop technologies or products – he wants to build long-lasting businesses based upon big ideas.” Written by our Chief Commercial Officer Chris Baldwin, this Sharecafe article explains Dr Dixon’s big idea back in 2013 and how it led to the foundation of Exopharm. Today, Exopharm is […]

Biotech Daily’s Tim Boreham likes Exopharm’s focus: “Given the scientifically complex nature of Exopharm’s quest to develop exosomes into therapeutics, it’s good to see that founder and chief executive Ian Dixon hasn’t lost sight of the commercial basics.” Read the full article here.  

MST Access, a division of MST Financial which provides institutional-grade research for small and medium cap companies, has initiated coverage of Exopharm Ltd (ASX: EX1). Read the full report here.

Their Curiosity and Enthusiasm are Infectious… Recently Chief Commercial Officer Chris Baldwin sat down with StockPal to discuss the CEO mindset. Read Chris’ thoughts on Exopharm, measuring success, and the future of exosome medicines. Read the full article on Stockpal Asia.  

BD Team Welcomes Partners The Business Development team is excited to be participating in the virtual “Bio Digital Partnering Convention 2020.”  With over 30 meetings with potential business partners from around the globe already planned, they are eager to find partners to help us in our mission to bring exosome medicines to the world. Other […]

Exopharm backs regulatory crackdown on unapproved exosome products A leading developer of exosome therapies, Australia-based Exopharm Limited, supports the US Food & Drug Administration (FDA) in highlighting the health dangers of unapproved products peddled by clinics that are openly flouting the rules. In a public safety notification released on December 6, the FDA highlighted reports […]

Exosomes vs Stem Cells: Exosomes as the Next Big Thing after Stem Cell Therapy The exosomes (or ‘extracellular vesicles’) released by stem cells may be the disruptive therapy for tackling age-related diseases doctors and patients have been waiting for. Despite over a decade and a half of hope and hype, stem cell therapy has failed […]

Exopharm: Reducing Risk. Making Drugs by Purifying not Synthesising In this note to shareholders and potential investors, the company outlines Exopharm’s risk-profile and how the business of Exopharm compares with other types of listed biotechnology companies. Exopharm: Context Exopharm is an ASX listed regenerative medicine company focused on bringing exosomes into clinical use as a […]

Exosomes (or extra cellular vesicles) are a new way to treat medical conditions including health span related medical problems. Exosomes are showing a great deal of promise in the Biotech industry as the future of regenerative medicine. What Are Exosomes? Exosomes are tiny packages of biomolecules released by cells1. They range between 40 and 200 […]

Biotech and Exosome Investment Growth Recent financial transactions highlight increasing biotech investment activity in the field of exosomes and extracellular vesicles. These naturally occurring packets of biomolecules could represent a new paradigm in healthcare. Exopharm Limited (ASX-EX1) is one of a small number of Australian biotech stocks currently attracting investors in regenerative medicine, and its […]

The Critical Bottleneck of Exosome Isolation and the Power of Exopharm’s LEAP Technology Why Exopharm is poised to be a leader in the field of therapeutic exosomes. Exosomes (also known as extracellular vesicles or EVs) from stem cells are poised to become a new form of regenerative medicine – described by some as the ‘secret […]

Regenerative Medicine: Questions and Answers What is regenerative medicine? Regenerative medicine is a term used to cover different ways scientists can harness the body’s own regenerative capabilities. What are some examples of regenerative medicines? An old example is blood. Blood (or blood plasma) from donors is used routinely in hospitals if the patient needs more […]

Meet the Exosomes Exactly a decade ago, a seminal paper revealed the role exosomes play in the body. Read on for Exopharm’s guide on what exosomes are, and why they’re beginning to create a buzz in medical circles. Human cells are a gregarious bunch – otherwise we would fall apart. They continually message each other, […]

Exosomes Linking Obesity and Diabetes Exosomes from lean individuals can reverse the symptoms of diabetes associated with obesity, a new animal study shows Inflammatory exosomes are the missing link by which obesity causes type 2 diabetes, researchers from the University of California San Diego have shown. The discovery could lead to earlier diabetes diagnosis and […]

Could exosome therapy help athletes recover from injury faster – and help the rest of us by mimicking the whole-body benefits of exercise? Some people don’t get enough physical exercise – but others suffer from too much activity, injury and over-training. Many sports players are set to benefit from the dawning era of exosome medicine. […]

Exosomes as Drug Delivery Vehicles: Natural Nano-bio-drones In the not too distant future, click ‘buy’ on an internet shopping site and an autonomous drone will be dispatched to carry your new goods directly to your doorstop. For now, drone home-delivery is still science fiction – but inside the body, targeted autonomous delivery of packages is […]